雷帕霉素药物洗脱支架直接置入术治疗急性冠脉综合征的临床研究

Comparison of CYPHER^(TM) stenting with or without predilation for "Culprit" lesions in the patients with acute coronary syndrome

目的 评价直接置入雷帕霉素药物洗脱支架 (CYPHERTM,codis)治疗急性冠脉综合征 (ACS)罪犯病变的安全性、可行性。方法 32例接受CYPHERTM支架直接置入的患者 (直接支架组 )和一般情况匹配的 34例球囊扩张后行冠脉支架术的患者 (常规支架组 ) ,比较两组的一般情况 ,冠脉造影及介入治疗即刻和临床随访结果。结果 直接支架组和常规支架组的成功率分别为 97%和 10 0 % ,直接支架组 1例支架无法通过病变 ,球囊预扩张后成功置入原支架。两组无一例发生介入治疗相关的的严重心脏事件。随访期间两组严重心脏不良事件发生率无明显统计学差异。结论 CYPHERTM支架直接置入术治疗ACS罪犯病变安全可行 ,成功率高。

Objective To assess the clinical efficacy of direct stenting (DS) and conventional post-dilation stenting (CS) for Culprit lesions in patients with acute coronary syndrome. Methods Demographic characters ,final balloon dilation pressure, instent angiographic results,and long term outcomes were compared between patients receiving DS (n=32) and patients receiving CS(n=34). Results In CS group,all the patients failed due to angle in 'Culprif' lesion, which were successfully managed with pre-dilatian .There were no procedure-related death, re-infarction,or emergency bypass surgery in both groups.During the follow up period ,there was no significant difference between DS group and CS group in major adverse cardiac events (MACE). Conclusion It is safe and feasible to treat Culprit lesion with DS.